3,546 Lawsuits and Counting: Why GLP-1 Gastroparesis Is 2026's Fastest-Growing Mass Tort

The weight loss drug revolution has a dark side — and the legal system is catching up fast.

As of April 1, 2026, 3,546 lawsuits are pending in MDL 3094 against Novo Nordisk and Eli Lilly in the Eastern District of Pennsylvania. Over 100 new cases were filed in February 2026 alone. The numbers are accelerating.

What's Driving the Litigation

The core allegation: GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound cause severe gastrointestinal injuries that manufacturers failed to adequately warn about.

The injury breakdown in federal filings tells the story:

• 75% allege gastroparesis (stomach paralysis)
• 18% allege ileus (intestinal blockage)
• 18% allege bowel obstruction
• 8% allege gallbladder injuries

Many plaintiffs report that digestive issues persisted even after stopping the medication — suggesting permanent or long-lasting damage.

The Signal Was There

LEWS has been tracking GLP-1 adverse event signals across multiple data sources since early 2025. Our system aggregates intelligence from the FDA Adverse Event Reporting System (FAERS), peer-reviewed medical literature, consumer complaint forums, court filings, and regulatory actions.

Here's what the data shows:

• Nearly 500 deaths linked to semaglutide (Ozempic, Wegovy, Rybelsus) in FAERS
• 22,287 adverse reaction records for semaglutide alone
• 900+ adverse events reported for compounded semaglutide and tirzepatide, including 17 deaths
• 14,700+ published research papers flagged in our system discussing GLP-1 safety concerns

The signal-to-litigation pipeline is textbook: adverse events appear in FDA databases months before they surface in courtrooms. Firms that monitor these early signals gain a critical first-mover advantage.

The Label Problem

Ozempic's label states the drug is "not recommended in patients with severe gastroparesis." But plaintiffs argue this warning is buried and insufficient — and that Novo Nordisk knew about the risk far earlier than the warning suggests.

Meanwhile, Novo Nordisk received an FDA warning letter for failing to investigate and report treatment-emergent adverse events associated with semaglutide. That's a powerful fact for plaintiff attorneys arguing the company prioritized sales over safety.

What Comes Next

• Bellwether trials are expected in late 2026 or early 2027
• Settlement analysts project $200,000-$500,000 per severe gastroparesis case
• Total projected liability exceeds $2 billion
• Mass settlements are unlikely before late 2027

For Plaintiff Firms: The Window Is Now

GLP-1 litigation is past the "is this real?" phase but well before the "everyone's doing it" phase. The firms building their caseloads now — armed with early signal intelligence — will be best positioned when bellwether trials set the tone.

LEWS tracks 46 on-market products across 13 signal types and 12 data sources. Our system identified GLP-1 gastroparesis as a first-mover opportunity before the MDL was even formed.

The best time to build a GLP-1 practice was a year ago. The second best time is today.